Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102397
Revised: December 4, 2024
Accepted: February 6, 2025
Published online: April 24, 2025
Processing time: 161 Days and 3.2 Hours
Gastric cancer (GC) is one of the most common malignancies worldwide, and Helicobacter pylori (HP) infection is a well-established risk factor for its develo
To perform a meta-analysis to assess the relationship between HP and PD-L1 expression in patients with GC.
A systematic literature review was conducted using PubMed, Embase, Cochrane Library, and Web of Science databases. Observational studies that examined the association between HP infection and PD-L1 expression in patients with GC were included. Odds ratios and 95% confidence intervals were calculated to estimate the association. Heterogeneity was assessed using Cochrane’s Q test and I² statistic. A random-effects model was used due to significant heterogeneity across studies.
Fourteen studies involving a total of 3069 patients with GC were included. The pooled analysis showed a significant association between HP infection and increased PD-L1 expression in GC tissues (odd ratio = 1.69, 95% confidence interval: 1.24-2.29, P < 0.001, I2 = 59%). Sensitivity analyses confirmed the robustness of these findings. Subgroup analyses did not show significant variation based on geographic region, sample size, or method of PD-L1 assessment. Publication bias was minimal, as shown by funnel plots and Egger’s regression test.
HP infection is associated with increased PD-L1 expression in GC, suggesting that HP status may influence the response to programmed cell death protein 1/PD-L1 blockade therapy.
Core Tip: This meta-analysis investigated the relationship between Helicobacter pylori infection and programmed death-ligand 1 expression in gastric cancer (GC). Fourteen studies with 3069 GC patients were included. Results showed a significant association. Sensitivity and subgroup analyses confirmed the robustness. Publication bias was minimal. Helicobacter pylori infection may influence the response to programmed cell death protein 1/programmed death-ligand 1 blockade therapy in GC patients, but further research is needed to clarify the underlying mechanisms and clinical implications.
